Abivax completes enrollment in ABTECT trials

Abivax (ABVX) announced the completion of enrollment for the Phase 3 ABTECT trials in patients with moderately to severely active ulcerative colitis. Marc de Garidel, Chief Executive Officer of Abivax, commented: “Completing enrollment for our Phase3 ABTECT trials-one of the largest and fastest enrolling ulcerative colitis programs of its kind ever conducted-is a landmark achievement for both Abivax and the UC patient community. Obefazimod has already shown compelling potential to address the significant unmet needs of patients with moderately to severely active disease. We remain fully committed to advancing this pivotal program: we expect to report top-line induction results in Q32025, followed by comprehensive long-term maintenance data in Q22026. Should these data confirm obefazimod’s safety and efficacy, we plan to submit a New Drug Application to the FDA in the second half of 2026, bringing us ever closer to delivering a desperately needed new therapeutic option.”